[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338449-105":59,"doc-detail-338449-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","lncrna-casc9-facilitates-papillary-thyroid-cancer-development-and-doxorubicin-resistance-via-mir-28-3pbcl-2-axis-and-pi3kakt-signaling-pathway","LncRNA CASC9 facilitates papillary thyroid cancer development and doxorubicin resistance via miR-28-3p/BCL-2 axis and PI3K/AKT signaling pathway","","Papillary thyroid cancer is a malignant disease threatening human health, and long noncoding RNA CASC9 is implicated as an oncogene in multiple tumors. This study investigates how LncRNA CASC9 regulates doxorubicin resistance in papillary thyroid cancer. CASC9, miR-28-3p, and BCL-2 levels are measured in patient tissues and doxorubicin-resistant cells, with cellular phenotypes assessed by proliferation, apoptosis, migration, and IC50 assays. Mechanistic validation uses dual-luciferase reporter and rescue approaches, including in vivo xenograft experiments.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/lncrna-casc9-facilitates-papillary-thyroid-cancer-development-and-doxorubicin-resistance-via-mir-28-3pbcl-2-axis-and-pi3kakt-signaling-pathway/338449/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/lncrna-casc9-facilitates-papillary-thyroid-cancer-development-and-doxorubicin-resistance-via-mir-28-3pbcl-2-axis-and-pi3kakt-signaling-pathway/338449.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main purpose of studying LncRNA CASC9 in papillary thyroid cancer?","Question",{"text":112,"@type":113},"To explore the mechanism by which LncRNA CASC9 regulates doxorubicin resistance in papillary thyroid cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the study assess doxorubicin resistance and related cellular behaviors?",{"text":117,"@type":113},"It determined CASC9, miR-28-3p, and BCL-2 expression and used CCK-8, colony formation, flow cytometry, and transwell assays to evaluate IC50, proliferation, apoptosis, and migration.",{"name":119,"@type":110,"acceptedAnswer":120},"What signaling pathway and molecular axis are implicated in CASC9’s effect?",{"text":121,"@type":113},"CASC9 promotes tumor progression by activating the PI3K/AKT signaling pathway and acts through the miR-28-3p/BCL-2 axis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338449,1790968670,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},962075114765,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Yu etal. Journal of Cardiothoracic Surgery (2024) 19:629  \n[https://doi.org/10.1186/s13019-024-03129-4](https://doi.org/10.1186/s13019-024-03129-4)  \nJournal of Cardiothoracic Surgery  \nRESEARCH Open Access  \nLncRNA CASC9 facilitates papillary thyroid  cancer development and doxorubicin resistance via miR-28-3p/BCL-2 axis and PI3K/ AKT signaling pathway  \nJianping Yu 1, Chun He 1, Yun Peng 1, YuzhongWen 1 and Jing Wang2*  \nAbstract  \nBackground Papillary thyroid cancer (PTC) is a malignant tumor that poses a serious threat to human health. LncRNA CASC9 serves as an oncogene in numerous tumors. The purpose of this study was to explore the mechanism of lncRNA CASC9 regulating doxorubicin (Dox) resistance in PTC.  \nMethods The expression of CASC9, miR-28-3p and BCL-2 in PTC tissues or dox-resistant cells was determined by quantitative real-time polymerase chain reaction (qRT-PCR) or western blot (WB) . CCK-8, colony formation assay, flow cytometry and transwell assay were used to measure the semi-inhibitory concentration (IC50) of dox, cell proliferation, apoptosis and migration, respectively. Dual luciferase reporter gene assays were performed to verify the targeting relationship between miR-28-3p and CASC9 or BCL-2 . Rescue experiments were applied to verify the mechanism of CASC9 . Finally, the role of CASC9 was verified by xenograft modeling in vivo.  \nResults We discovered that CASC9 was enhanced in PTC tissues, cells and Dox-resistant cells (BCPAP/Dox and K1/ Dox) . Furthermore, CASC9 inhibition markedly restrained the proliferation, migration and facilitated apoptosis of Dox cells. In vivo experiments also showed that silencing of CASC9 inhibited tumor growth. Meanwhile, knockdown of CASC9 sensitized PTC cells to Dox. CASC9 enhanced tumor progression by activating the PI3K/AKT signaling pathway. Furthermore, bioinformatics analysis identified miR-28-3p as a downstream target of CASC9 . MiR-28-3p inhibitor reversed the impact of CASC9 knockdown in BCPAP/Dox and K1/Dox. Further studies showed that CASC9 positively regulated BCL-2 expression through miR-28-3p. miR-28-3p weakened Dox resistance, proliferation, migration and accelerated apoptosis of PTC cells via BCL-2 .  \nConclusion CASC9, as an oncogenic lncRNA, has a promotional effect on Dox resistance and PTC progression via miR-28-3p/BCL-2 axis and PI3K/AKT signaling pathway.  \nKeywords Papillary thyroid cancer, lncRNA CASC9, miR-28-3p, BCL-2, Doxorubicin  \n*Correspondence:  \nJing Wang  \n[wangjingnc68@163.com](wangjingnc68@163.com)  \n1Thyroid Surgery, Ganzhou People’s Hospital, Ganzhou, Jiangxi 341000, China  \n2Intensive Care Unit, Ganzhou People’s Hospital, No.16 Meiguan Avenue, Zhanggong District, Ganzhou, Jiangxi 341000, China  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \nYu et al. Journal of Cardiothoracic Surgery (2024) 19:629  \nIntroduction  \nThyroid cancer is the most common endocrine malignancy, accounting for 95% of endocrine tumors. Its incide","cbCainloVGVfvI35","https://ap.wps.com/l/cbCainloVGVfvI35","pdf",6875160,13,"English","# Abstract\n# Introduction\n## Background and clinical context\n## Role of noncoding RNAs and lncRNAs\n# Methods\n## Expression and molecular assays\n## Functional assays and phenotypic measurements\n## Target verification and rescue experiments\n## In vivo xenograft validation","[{\"question\":\"What is the main purpose of studying LncRNA CASC9 in papillary thyroid cancer?\",\"answer\":\"To explore the mechanism by which LncRNA CASC9 regulates doxorubicin resistance in papillary thyroid cancer.\"},{\"question\":\"How did the study assess doxorubicin resistance and related cellular behaviors?\",\"answer\":\"It determined CASC9, miR-28-3p, and BCL-2 expression and used CCK-8, colony formation, flow cytometry, and transwell assays to evaluate IC50, proliferation, apoptosis, and migration.\"},{\"question\":\"What signaling pathway and molecular axis are implicated in CASC9’s effect?\",\"answer\":\"CASC9 promotes tumor progression by activating the PI3K/AKT signaling pathway and acts through the miR-28-3p/BCL-2 axis.\"}]","LncRNA CASC9 facilitates papillary thyroid cancer development and doxorubicin resistance via miR-28-3p/BCL-2 axis and PI3K/AKT signaling pathway | PDF",1790023668,33]